Log In
BCIQ
Print this Print this
 

XLRS (rAAV2tYF-CB-hRS1)

  Manage Alerts
Collapse Summary General Information
Company Applied Genetic Technologies Corp.
DescriptionRecombinant adeno-associated virus (AAV) vector delivering retinoschisis X-linked juvenile 1 (RS1; XLRS1)
Molecular Target Retinoschisis X-linked juvenile 1 (RS1) (XLRS1)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPhase I/II
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat X-linked juvenile retinoschisis; Treat X-linked retinoschisis (XLRS)
Regulatory Designation
PartnerBiogen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,189.0M

0

$1,065.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/02/2015

$1,189.0M

Undisclosed

$1,065.0M

Get a free BioCentury trial today